The Botulinum Toxin and Cosmetic Fillers (Children) Bill passed its second reading in the House of Lords on April 16.
As lockdown lifts patients will request non-invasive procedures without downtime
2021 is a milestone year for global aesthetics leader Galderma, who celebrate their 40th anniversary this year.
The Aesthetic Complications Expert (ACE) Group World has released new guidance on dermal filler delayed onset reactions following COVID-19 infection and vaccination.
The Royal Society for Public Health (RSPH) has partnered with the newly-established Qualification Council for Cosmetic Procedures (QCCP) to launch new aesthetic qualifications for healthcare professionals.
Global pharmaceutical company Galderma has received top-line results for its phase 2 study in the US on the efficacy and safety of a single dose of abobotulinumtoxinA versus placebo for the treatment of moderate to severe glabellar lines.
A new study published in Plastic and Reconstructive Surgery has suggested that intradermal botulinum toxin injection, or microbotulinum, is a safe and effective method to treat skin flaws.
According to a report published by Fortune Business Insights, the botulinum toxin market will reach US $8,309 million by 2026, exhibiting a compound annual growth rate of 8%.
The Advertising Standards Authority (ASA) has provided practitioners with further advice for social media advertising to avoid having their adverts removed for not complying with the Enforcement Notice published in January.
The Joint Council for Cosmetic Practitioners (JCCP) has released a 15-point plan in response to the second reading of the ‘Botulinum Toxin and Cosmetic Fillers (Children) Bill 2019-2021’ to assist the Government formulate a coherent policy response to improve regulation throughout the aesthetics specialty.